<?xml version="1.0" encoding="UTF-8"?>
<p>Neuraminidase inhibitors are widely used for treatment (and sometimes prevention) of influenza infection, and they have demonstrated efficacy. However, new drugs are needed to reach better treatment results in vulnerable patient groups particularly in the scenario of developing antiviral resistance. Several new antiviral drugs against influenza have been developed or are under development, including polymerase inhibitors and monoclonal antibodies. These new drugs are reviewed in the paper by 
 <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmed.2019.00109" xmlns:xlink="http://www.w3.org/1999/xlink">Principi et al.</ext-link>.
</p>
